Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in Combination With Other Drugs for Advanced Solid Tumour
NCT07111546Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of opamtistomig in biliary tract cancer (BTC) and hepatocellular carcinoma (HCC) (2 cohorts), sponsored by Leads Biolabs. Primary endpoint: Objective Response Rate. Started Oct 2025; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
biliary tract cancer (BTC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07111546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111546.